Cabaletta Bio (CABA) received a Buy rating from Cowen & Co. analyst Phil Nadeau today. The company’s shares closed last Monday at $13.79.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.2% and a 46.8% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
The the analyst consensus on Cabaletta Bio is currently a Moderate Buy rating.
See today’s analyst top recommended stocks >>
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CABA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies.
